Title
Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
Phase
Phase 3Lead Sponsor
Food and Drug AdministrationStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Cystic Fibrosis Bacterial InfectionIntervention/Treatment
tobramycin ...Study Participants
200OBJECTIVES: I. Determine the safety and efficacy of tobramycin in patients with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa.
II. Determine whether this treatment produces tobramycin-resistant bacteria at a frequency different from the placebo group and whether the emergence of resistance is associated with a lack of clinical response.
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.
Patients receive tobramycin or placebo by inhalation twice daily for 28 days followed by 28 days of rest. This treatment is repeated twice, for a total of 3 courses of therapy.
Patients are followed every 2 weeks for the first 8 weeks, then every 4 weeks, and then at 4 weeks after the last treatment.
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Documented cystic fibrosis with Pseudomonas aeruginosa present in a sputum or throat culture within 6 months prior to screening Sweat chloride at least 60 mEq/L --Prior/Concurrent Therapy-- At least 14 days since prior intravenous or aerosolized tobramycin or other antipseudomonal antibiotic At least 4 weeks since prior administration of any investigational drug No concurrent antibiotics by aerosol --Patient Characteristics-- Renal: Creatinine less than 2 mg/dL BUN less than 40 mg/dL No proteinuria of 2+ or greater Pulmonary: FEV1 at least 75% and at least 25% of predicted Room air oximetry at least 88% saturation Able to perform pulmonary function tests No hemoptysis of 60 mL or greater within 30 days prior to study No abnormal chest X-ray Other: Not pregnant Fertile females must use effective contraception No history of positive culture with Burkholderia cepacia No history of glucose-6-phosphate dehydrogenase deficiency No known local or systemic hypersensitivity to aminoglycosides, albuterol, or other beta-2 agonists
